MAP Pharmaceuticals Inc. (Nasdaq: MAPP) shares are down about 9 percent near $10, on opening volume of about 30,000 shares. The stock is reacting to plans to suspend its asthma drug candidate Unit Dose Budesonide, after licensing partner AstraZeneca (NYSE: AZN) decided to modify a collaboration agreement. — Mike Tarsala
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment